Wednesday, September 28, 2022

Clinical trial to begin with Cuban drug against Alzheimer’s (+ video)

will start soon The drug’s Phase III clinical trial was born in CubaFinal against Alzheimer’s, neuralcim-cum nameNeuroEPO Commercial – for which they have just started with the classification consultation of patients in Havana yesterdayyou will attend study.

Although this test The first does not necessarily mean the full start of clinical testing, it constitutes an important step forward in the correct diagnosis of patients and identification of the population to be included, the doctor of science explained to the press this Wednesday. kelet leon somZone, First Deputy Director Center for Molecular Immunology (CIM) K.

Clinical trial to begin with Cuban drug against Alzheimer's (+ video)

of the sites in the capital where you can request For consultation there are the Shift Medical-Surgical Research Center (CIMEC), and Salvador Allende, Manuel Fajardo, Hermanos Amjeiras Hospital, as well as the Institute of Neurology.

doctor of science Leslie Perez Ruiz, promoter of CIM’s Alzheimer’s clinical trial, pointed out that, currentlymind, you have one Database of over 400 patients, of which 371 are from Havana.

He said 310 of the caregivers who have been traced can call and have been assigned a shift for counseling, in which it will be identified if the patient has a mild/moderate pattern of Alzheimer’s.

According to Dr. Perez Ruiz, Phase III of the study is likely to begin next September or October, and seeks to evaluate the efficacy and safety of this formulation for nasal administration.

Clinical trial to begin with Cuban drug against Alzheimer's (+ video)

In this sense, he explained that NeuralCIM will be compared to drug with donepezil accepted for decades In the 1990s by the US Drug Regulatory Agency, meanwhile, for the first time in Cuba, the patient would be given a molecular diagnosis for Alzheimer’s, not just a clinical one.

He added that Phase IV trials will be conducted in the rest of the country in patients with mild/moderate disease phenotype (amnesic variant), who will be clinically diagnosed only.

Dr. Perez Ruiz also said that the drug will be administered by a home caregiver, who will be trained in health institutions for the correct administration of NeuralCIM.

Details for participating in the test

With regard to patient classification questions for Phase III clinical trials in mild and moderate Alzheimer’s, BiocubaPharma published a note explaining that anyone wishing to participate must first request an appointment through the contacts provided on continuation should do.

He also specified that this phase is for the classification of patients, and that those who meet the selection requirements will be included in the clinical trial, which is expected to begin in September after being approved by Cuba’s regulatory agency. hopefully. CECMED.

Clinical trial to begin with Cuban drug against Alzheimer's (+ video)
photo: Molecular Immunology Center

Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -